Meglumine Diatrizoate Injection Market Overview
The global Meglumine Diatrizoate Injection market was valued at USD 700 million in 2024 and is expected to grow from USD 800 million in 2025 to USD 1.2 billion by 2035, registering a CAGR of 4.4% during the forecast period from 2025 to 2035. Increasing diagnostic imaging procedures, rising demand for contrast agents, the growing prevalence of chronic diseases, technological advancements in radiology, and increasing healthcare infrastructure investments are supporting market expansion.
North America is anticipated to remain the leading regional market, valued at USD 320 million in 2024 and projected to reach USD 480 million by 2035. Among applications, CT scans represented a significant segment, valued at USD 240 million in 2024 and expected to reach USD 360 million by 2035. Hospitals are expected to remain the primary end users as demand for contrast media increases across diagnostic procedures.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/reports/meglumine-diatrizoate-injection-market
Key Companies in the Meglumine Diatrizoate Injection Market
Bayer
Otsuka Pharmaceutical
B. Braun Melsungen
Millennium Pharmaceuticals
Lantheus Medical Imaging
Eisai
Guerbet
Radiosyn
Janssen Pharmaceuticals
Fujifilm
GE Healthcare
Baxter International
Daiichi Sankyo
Hengrui Medicine
AngioDynamics
The market is being driven by the increasing utilization of contrast media in radiography, CT scans, angiography, and urography. The growing incidence of chronic and cardiovascular diseases is increasing the need for accurate diagnostic imaging, while an aging population is contributing to higher demand for medical imaging services. Advances in digital radiography and CT technologies are also improving diagnostic capabilities and creating opportunities for effective contrast agents.
The Meglumine Diatrizoate Injection Market is segmented by application, end use, administration route, and region. Applications include radiography, CT scans, angiography, and urography. End users comprise hospitals, diagnostic imaging centers, and research laboratories. Administration routes include intravenous, intraarterial, and intrathecal delivery, while regional coverage includes North America, Europe, South America, Asia Pacific, and the Middle East and Africa.
Recent Developments and Market Trends:
Guerbet announced a strategic partnership with Fujifilm in March 2025 to co-develop and commercialize iodinated contrast media solutions for the Asian market.
Bayer completed the acquisition of a regional radiology contrast-media distributor in October 2024 to strengthen its supply-chain footprint.
Lantheus Medical Imaging announced the launch of a next-generation iodinated contrast agent for CT imaging in May 2025.
CT scans continue to represent an important application as healthcare providers increasingly rely on detailed cross-sectional imaging for diagnosis.
Advancements in radiology and imaging technologies are improving diagnostic accuracy and supporting demand for contrast agents.
Asia Pacific is emerging as a significant growth region due to increasing healthcare investment, improving diagnostic infrastructure, and rising demand for imaging procedures.
Reasons to Buy the Report:
Understand the current market size, growth trajectory, and forecast of the global Meglumine Diatrizoate Injection Market through 2035.
Analyze key segments based on application, end use, administration route, and region.
Evaluate regional opportunities across North America, Europe, Asia Pacific, South America, and the Middle East and Africa.
Identify major companies and understand their competitive positioning in the global contrast-media market.
Assess the impact of diagnostic imaging demand, chronic diseases, technological advancements, and healthcare infrastructure investments.
Understand emerging opportunities associated with advanced imaging technologies, improved contrast-agent formulations, and expanding diagnostic services.
Future Outlook:
The global Meglumine Diatrizoate Injection Market is expected to maintain steady growth through 2035 as diagnostic imaging procedures continue to expand worldwide. Increasing demand for CT scans and radiographic examinations, a growing elderly population, rising chronic disease prevalence, and improvements in imaging technology are expected to sustain market opportunities. Continued investment in healthcare infrastructure, safer contrast-media formulations, and regulatory-compliant imaging solutions is likely to further support market development.
➤➤Explore Our Latest Related Reports:
